Citi analyst Joanne Wuensch maintains $Medtronic (MDT.US)$ with a hold rating, and sets the target price at $92.
According to TipRanks data, the analyst has a success rate of 64.0% and a total average return of 6.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Medtronic (MDT.US)$'s main analysts recently are as follows:
Speculation is raised on whether the recent surge in medical technology stocks is sustainable as the industry approaches third-quarter financial disclosures. A cautious stance is advised entering earnings season, noting that the third quarter is traditionally challenging within the MedTech sector. It's a period that invites close evaluation of strategies leading up to 2025 and discussions regarding projections for the upcoming year that may influence stock performance in the short term.
In the Medical Technology sector, the ongoing positive trend in utilization is expected to continue into the third quarter, and the outlook for capital expenditures into the following year is considered robust. Specifically, within life science tools, bioprocess trends are anticipated to show signs of improvement as the second half progresses. However, there is ongoing discussion regarding the outlook for instruments and the impact of China's stimulus, particularly given the recent performance of stocks in this category. Medtronic, among other companies, has been identified for potential outperformance in the near term, while Exact Sciences continues to be recognized for its prospects as we approach the third-quarter financial disclosures.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
花旗分析師Joanne Wuensch維持$美敦力 (MDT.US)$持有評級，目標價92美元。
根據TipRanks數據顯示，該分析師近一年總勝率為64.0%，總平均回報率為6.4%。
此外，綜合報道，$美敦力 (MDT.US)$近期主要分析師觀點如下：
隨着該行業接近第三季度財務披露，人們開始猜測近期醫療科技股的飆升是否可持續。建議在進入業績期時採取謹慎的立場，並指出第三季度在醫療科技領域傳統上具有挑戰性。在此期間，我們需要對2025年之前的戰略進行仔細評估，並討論可能在短期內影響股票表現的來年的預測。
在醫療技術領域，持續的積極利用率趨勢預計將持續到第三季度，明年的資本支出前景被認爲是強勁的。具體而言，在生命科學工具方面，隨着下半年的推進，生物過程趨勢預計將顯示出改善的跡象。但是，關於工具前景和中國刺激措施影響的討論仍在繼續，特別是考慮到該類別股票的近期表現。美敦力等公司已被確定在短期內可能跑贏大盤，而隨着第三季度財務披露的臨近，Exact Sciences的前景繼續獲得認可。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
